A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women

Trial Profile

A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Enobosarm (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors GTx
  • Most Recent Events

    • 31 Jul 2017 Planned End Date changed from 1 Aug 2018 to 1 Mar 2019.
    • 31 Jul 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Sep 2017.
    • 31 Jul 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top